Entera Bio Net Worth
Entera Bio Net Worth Breakdown | ENTX |
Entera Bio Net Worth Analysis
Entera Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Entera Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Entera Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Entera Bio's net worth analysis. One common approach is to calculate Entera Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Entera Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Entera Bio's net worth. This approach calculates the present value of Entera Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Entera Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Entera Bio's net worth. This involves comparing Entera Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Entera Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Entera Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Entera Bio's net worth research are outlined below:
| Entera Bio may become a speculative penny stock | |
| Entera Bio had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 14 K. Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 33 K. | |
| Entera Bio currently holds about 17.28 M in cash with (7.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Entera Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company shares are held by company insiders |
Entera Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Entera Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Entera Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Entera Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Entera Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Entera Bio backward and forwards among themselves. Entera Bio's institutional investor refers to the entity that pools money to purchase Entera Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2024-03-31 | 0.0 | Two Sigma Securities, Llc | 2024-03-31 | 0.0 |
Follow Entera Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.51 M.Market Cap |
|
Project Entera Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.79) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.76) | (0.79) | |
| Return On Equity | (0.86) | (0.90) |
When accessing Entera Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Entera Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Entera Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Check Entera Bio's Beneish M Score to see the likelihood of Entera Bio's management manipulating its earnings.
Evaluate Entera Bio's management efficiency
Entera Bio has return on total asset (ROA) of (0.7061) % which means that it has lost $0.7061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4467) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2024. Return On Capital Employed is likely to drop to -0.87 in 2024. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 209 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.36 | 0.38 | |
| Tangible Book Value Per Share | 0.36 | 0.38 | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | 1.68 | 1.76 | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | 1.68 | 1.76 | |
| Enterprise Value | 6.8 M | 6.4 M |
Understanding the operational decisions made by Entera Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 524.8205 | Revenue 99 K | Quarterly Revenue Growth (0.92) | Revenue Per Share 0.003 | Return On Equity (1.45) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entera Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Entera Bio time-series forecasting models is one of many Entera Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entera Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Entera Bio Earnings per Share Projection vs Actual
Entera Bio Corporate Management
| Hillel MBA | Chief Officer | Profile | |
| Miranda MBA | CEO Director | Profile | |
| II MD | Chief Officer | Profile | |
| Gregory Burshtein | Chief Development | Profile | |
| Dana CPA | Chief Officer | Profile |
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.